# To Evaluate the Safety and Efficacy of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With COVID-19 Not Requiring Supplemental Oxygen

> **NCT05224856** · PHASE3 · WITHDRAWN · sponsor: **Celltrion**

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** CT-P63 and CT-P66 / Placebo

## Key facts

- **NCT ID:** NCT05224856
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-04
- **Primary completion:** 2022-11
- **Final completion:** 2023-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The sponsor has decided to stop development of the inhaled CT-P63/66 combination therapy.
- **Last updated:** 2022-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05224856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05224856, "To Evaluate the Safety and Efficacy of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With COVID-19 Not Requiring Supplemental Oxygen". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05224856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*